Argitalpenak (457) Ikertzaileren baten partaidetza izan duten argitalpenak

2024

  1. A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death

    Scientific reports, Vol. 14, Núm. 1, pp. 3000

  2. Aplicación racional de las recomendaciones ESPGHAN 2022 de seguimiento del paciente celíaco pediátrico: documento de consenso de sociedades científicas (SEGHNP, AEPap, SEPEAP, SEEC, AEG, SEPD, SEMFYC, SEMG y SEMERGEN)

    Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP ), Vol. 101, Núm. 4, pp. 267-277

  3. Biological variability of human intraepithelial lymphocytes throughout the human gastrointestinal tract in health and coeliac disease

    European Journal of Clinical Investigation

  4. Calcium, Phosphate, and Vitamin D in Children and Adolescents with Chronic Diseases: A Cross-Sectional Study

    Nutrients, Vol. 16, Núm. 9

  5. Calcium, Phosphorus, and Vitamin D Levels in a Series of Cystic Fibrosis Patients: A Cross-Sectional Study

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

  6. Circulating immunome fingerprint in eosinophilic esophagitis is associated with clinical response to proton pump inhibitor treatment

    Frontiers in Immunology, Vol. 15

  7. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  8. Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease

    Gastroenterologia y Hepatologia

  9. Human intestinal spirochetosis: an entity associated with sexual transmitted infections

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 42, Núm. 5, pp. 231-235

  10. Intensification with Intravenous Ustekinumab in Refractory Crohn’s Disease

    Journal of Clinical Medicine, Vol. 13, Núm. 3

  11. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management

    United European Gastroenterology Journal, Vol. 12, Núm. 1, pp. 122-138

  12. Selective granulocyte–monocyte apheresis during induction with vedolizumab in moderate–severe ulcerative colitis: Experience in a tertiary hospital

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 721-726

  13. Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients

    Inflammatory Bowel Diseases, Vol. 30, Núm. 2, pp. 167-182

  14. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  15. State-of-the-art cytometry in the search of novel biomarkers in digestive cancers

    Frontiers in Oncology, Vol. 14

  16. Tendencia creciente de pacientes con condiciones limitantes para la vida y crónicos complejos

    Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP ), Vol. 101, Núm. 2, pp. 95-103

  17. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5